Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906448 | 1.00 | PTPN11 (0.54) | PTPN11ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL4906517 | 0.91 | KDM4E (0.43) | PTPN11ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL4906515 | 0.91 | KDM4E (0.43) | PTPN11ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL4896236 | 0.87 | PTPN11 (0.53) | PTPN11ALDH1A1KMT2AMEN1NAMPT | |
| SCHEMBL4896246 | 0.87 | PTPN11 (0.53) | PTPN11ALDH1A1KMT2AMEN1NAMPT | |
| SCHEMBL4908777 | 0.85 | CDK2 (0.39) | PTPN11ALDH1A1KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL4908785 | 0.85 | CDK2 (0.39) | PTPN11ALDH1A1KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL4903841 | 0.84 | CDK2 (0.40) | PTPN11ALDH1A1KMT2APOLB | |
| SCHEMBL4903838 | 0.84 | CDK2 (0.40) | PTPN11ALDH1A1KMT2APOLB | |
| SCHEMBL14111974 | 0.83 | PTPN11 (0.52) | PTPN11ALDH1A1KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-24 | — | — | US | disclosed |
| WO-2007117699-A2 | INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | PTPN7, PTPN1, PTPN2 | PTPN11 16/4885ALDH1A1 3859/4885KMT2A 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.